The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …

Background We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody
against terminal complement protein C5 that inhibits terminal complement activation, in …

Patients with kidney failure are at increased risk of SARS-CoV-2 infection, making effective
vaccinations a critical need. It is not known how well mRNA vaccines induce B and plasma …

The terminal complement inhibitor eculizumab was recently shown to be effective and well
tolerated in patients with paroxysmal nocturnal hemoglobinuria (PNH). Here, we extended …

Hemolysis and hemoglobinemia contribute to serious clinical sequelae in hemolytic disorders.
In paroxysmal nocturnal hemoglobinuria (PNH) patients, hemolysis can contribute to …

Novel mRNA-based vaccines have been proven to be powerful tools in combating the global
pandemic caused by SARS-CoV-2, with BNT162b2 (trade name: Comirnaty) efficiently …

Interleukin-6 (IL-6) is a proinflammatory cytokine that has been shown to mediate, in addition
to immune reactions, various endocrine and central nervous components of the acute …

The decline in hematopoietic function seen during aging involves a progressive reduction in
the immune response and an increased incidence of myeloid malignancy, and has been …

Background and Methods. Immunosuppression is the most effective treatment for patients
with aplastic anemia, except for bone marrow transplantation. The best results are achieved …

Immunosuppression with antithymocyte globulin, (methyl)prednisolone, and cyclosporin A
is considered the treatment of choice for the patient with aplastic anemia without a donor for …